Enliven Therapeutics adds Kristine Ball to board; Phase 3 relcobatinib trial to start before year-end

Enliven Therapeutics, Inc.

Board expanded from seven to eight directors; Ball appointed Class II director effective Oct. 14, 2026, term expiring at the 2028 annual meeting, and joins the Audit Committee.
Compensation: $45,000/year as outside director plus $10,000/year for Audit Committee service, and stock options with grant-date fair value of about $650,000.
Options vest 1/36th monthly, with full acceleration on a Change in Control; Ball also signed the company's standard indemnification agreement.
Ball was CEO of Antiva Biosciences and Soteria Biotherapeutics and CFO of Menlo Therapeutics and Relypsa; she chairs Oruka Therapeutics' audit committee.
Company reaffirmed plans to initiate the pivotal Phase 3 trial of relcobatinib (ELVN-001) in previously treated CML before year-end 2026 after FDA alignment on ENABLE-2 design.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.